IWP
REGN icon

IAG Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

IAG Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.5K Hold
33
– – ﹤0.01% 275
2025
Q4 		$25.5K Hold
33
– – ﹤0.01% 270
2025
Q3 		$18.6K Buy
+33
New +$18.7K ﹤0.01% 310

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

IAG Wealth Partners's REGN Position: Q1 2026 in Review

IAG Wealth Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 33 shares worth $25.5K. The position accounts for ﹤0.01% of the portfolio, ranked #275.

IAG Wealth Partners first reported a position in REGN in Q3 2025 and has held it in 3 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • IAG Wealth Partners held 33 shares of Regeneron Pharmaceuticals worth $25.5K as of Q1 2026.
  • IAG Wealth Partners left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of IAG Wealth Partners's portfolio in Q1 2026, its #275 holding.
  • IAG Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on IAG Wealth Partners's 13F filing for Q1 2026, filed 29 Apr 2026.